Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01696994 · OUTCOME

Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial) · Source last updated 2026-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Diagnoses per 10,000 PY
Interval / dispersion
Not reported
Time frame
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

What was measured

Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer.

Analysis population: Female participants, excluding females without ovaries at baseline, were analyzed. An intention-to-treat analysis was performed.

Groups in this outcome

Control

Participants receive standard medical care.

Ovarian Screening

Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Control34304
Ovarian Screening34253

Reported measurements

Source class 1
Values in Diagnoses per 10,000 PY · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Control4.7Not reportedNot reportedNot reportedNot reported
Ovarian Screening5.7Not reportedNot reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.99
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.48
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    param Type
    Hazard Ratio (HR)
    param Value
    1.21
    statistical Method
    Poisson regression
Complete source fields
analyses
  1. ci Lower Limit
    0.99
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.48
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    param Type
    Hazard Ratio (HR)
    param Value
    1.21
    statistical Method
    Poisson regression
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        4.7
      2. group Id
        OG001
        value
        5.7
denoms
  1. counts
    1. group Id
      OG000
      value
      34304
    2. group Id
      OG001
      value
      34253
    units
    Participants
description
Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer.
groups
  1. description
    Participants receive standard medical care.
    id
    OG000
    title
    Control
  2. description
    Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years.
    id
    OG001
    title
    Ovarian Screening
param Type
NUMBER
population Description
Female participants, excluding females without ovaries at baseline, were analyzed. An intention-to-treat analysis was performed.
reporting Status
POSTED
time Frame
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
title
Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).
type
SECONDARY
unit Of Measure
Diagnoses per 10,000 PY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice